Free Trial

Biomea Fusion (BMEA) Stock Price, News & Analysis

Biomea Fusion logo
$6.28 -0.14 (-2.18%)
(As of 11/20/2024 ET)

About Biomea Fusion Stock (NASDAQ:BMEA)

Key Stats

Today's Range
$6.04
$6.55
50-Day Range
$6.28
$12.41
52-Week Range
$3.61
$22.74
Volume
552,219 shs
Average Volume
822,098 shs
Market Capitalization
$227.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.50
Consensus Rating
Buy

Company Overview

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Biomea Fusion Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
69th Percentile Overall Score

BMEA MarketRank™: 

Biomea Fusion scored higher than 69% of companies evaluated by MarketBeat, and ranked 351st out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Biomea Fusion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Biomea Fusion has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Biomea Fusion's stock forecast and price target.
  • Earnings Growth

    Earnings for Biomea Fusion are expected to grow in the coming year, from ($3.93) to ($3.84) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Biomea Fusion is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Biomea Fusion is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Biomea Fusion has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Biomea Fusion's valuation and earnings.
  • Percentage of Shares Shorted

    30.19% of the float of Biomea Fusion has been sold short.
  • Short Interest Ratio / Days to Cover

    Biomea Fusion has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Biomea Fusion has recently increased by 3.54%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Biomea Fusion does not currently pay a dividend.

  • Dividend Growth

    Biomea Fusion does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    30.19% of the float of Biomea Fusion has been sold short.
  • Short Interest Ratio / Days to Cover

    Biomea Fusion has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Biomea Fusion has recently increased by 3.54%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Biomea Fusion has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Biomea Fusion this week, compared to 3 articles on an average week.
  • Search Interest

    Only 2 people have searched for BMEA on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
  • MarketBeat Follows

    15 people have added Biomea Fusion to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Biomea Fusion insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,600.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    27.57% of the stock of Biomea Fusion is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.72% of the stock of Biomea Fusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Biomea Fusion's insider trading history.
Receive BMEA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter.

BMEA Stock News Headlines

Biomea Fusion’s icovamenib shows efficacy in Type 2 diabetes trial
[625,000% Gain] – Are You Ready for the Next Altcoin Boom?
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Truist Financial Remains a Buy on Biomea Fusion (BMEA)
Oppenheimer Reaffirms Their Buy Rating on Biomea Fusion (BMEA)
See More Headlines

BMEA Stock Analysis - Frequently Asked Questions

Biomea Fusion's stock was trading at $14.52 at the beginning of 2024. Since then, BMEA shares have decreased by 56.7% and is now trading at $6.28.
View the best growth stocks for 2024 here
.

Biomea Fusion, Inc. (NASDAQ:BMEA) released its quarterly earnings results on Tuesday, October, 29th. The company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.03.

Biomea Fusion (BMEA) raised $120 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 7,500,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO.

Biomea Fusion's top institutional shareholders include FMR LLC (14.99%), State Street Corp (1.77%), Geode Capital Management LLC (1.66%) and Charles Schwab Investment Management Inc. (0.58%). Insiders that own company stock include Bihua Chen, A2a Pharmaceuticals, Inc, Michael JM Hitchcock and Franco Valle.
View institutional ownership trends
.

Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biomea Fusion investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
10/29/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
4/07/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BMEA
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.50
High Stock Price Target
$60.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+385.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Net Income
$-117,250,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.74 per share

Miscellaneous

Free Float
26,248,000
Market Cap
$227.58 million
Optionable
Optionable
Beta
-0.41
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:BMEA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners